Clinical trials: Low Dose
Infertility
Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen
This is a single center, prospective, observational study on the use of Gonal-f in controlled ovarian hyperstimulation (COH) in subjects undergoing ovulation induction/ intrauterine insemination (OI/IUI) therapy across Taiwan.
- Trial name
- NCT01100346
- Testing
- Gonal-f (Follitropin alpha)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Low Back Pain
Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain
The purpose of this study is to determine the efficacy and safety of 1000 mg Aspirin (the study medication) by comparing it to placebo (the control group without active substance) or 400 mg Ibuprofen (the control group with an…
- Trial name
- NCT01028079
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465), Ibuprofen
- Where
- 13 sites in Germany, United Kingdom
- Volunteers
- 338 people
- Sponsor
- Bayer
Hormonal Intrauterine Contraception
The Aim of This Study is to Estimate the Discontinuation Rate of Low-dose Levonorgestrel-releasing Intrauterine System Due to Self-reported Unacceptable Menstrual Bleeding Pattern in Spanish Women Who Are Using it for the First Time How Intrauterine System for Long Acting Contraception
Researchers are looking for better ways to help women prevent pregnancy. Every month, a woman's body prepares for pregnancy in a process called the menstrual cycle. When pregnancy does not happen, menstruation occurs.
- Trial name
- CORA (NCT04785950)
- Testing
- Low-dose levonorgestrel intrauterine systems (LNG-IUS)
- Where
- Spain
- Volunteers
- 316 people
- Sponsor
- Bayer
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Iron Deficiency (Without Anemia)
Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels
This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting…
- Trial name
- NCT05257343
- Testing
- Liquid Iron Supplement (Blood Builder ®)
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Lung Cancer
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at…
- Trial name
- NCT05987189
- Testing
- Small RNA-based lung cancer assay
- Where
- 11 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Hummingbird Diagnostics
Hypertension, Type 2 Diabetes
Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.
- Trial name
- NCT00160160
- Testing
- eprosartan/HCTZ
- Where
- 63 sites in Canada, Denmark and 7 more
- Volunteers
- 440 people
- Sponsor
- Solvay Pharmaceuticals
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Myelodysplastic Syndrome
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
- Trial name
- NCT00458159
- Testing
- CC-11006
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Non-Hodgkin Lymphoma
EMD 521873 in Advanced Solid Tumors, MTD Finding
Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or…
- Trial name
- NCT01032681
- Testing
- EMD 521873
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormone Deficiency
Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients
An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months.
- Trial name
- NCT00570011
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Eli Lilly and Company
Kidney Cancer
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
- Trial name
- NCT00003181
- Testing
- aldesleukin, sargramostim, vinblastine sulfate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hope Cancer Institute, Inc.
Healthy Volunteer
A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers
This three-part study will evaluate the pharmacokinetics and bioavailability of intravenous danoprevir with and without low-dose oral ritonavir, and the effect of oral cyclosporine on the pharmacokinetics of intravenous…
- Trial name
- NCT01654211
- Testing
- danoprevir, ritonavir
- Where
- Netherlands
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Inclisiran Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a…
- Trial name
- NCT07626281
- Testing
- Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
- Where
- 6 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Lupus Erythematosus, Systemic
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
- Trial name
- DAHLIA (NCT07330245)
- Testing
- Anifrolumab
- Where
- 22 sites in Italy
- Volunteers
- 218 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcers
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
The purpose of this study is to evaluate the safety and preliminary efficacy of low dose nicotine gel in patients with chronic diabetic ulcers
- Trial name
- NCT00316537
- Testing
- ATG002 (study drug)
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- CoMentis
Low Back Pain, Low Back Pain, Recurrent
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe low back pain patients with a diagnosis of chronic low back pain.
- Trial name
- NCT00973024
- Testing
- JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg
- Where
- 60 sites in United States, Belgium and 2 more
- Volunteers
- 389 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.